CDEK
← All drugs Report issue

Gefurulimab

mAbexperimentalBi-specific

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Sep 4, 2019 (NCT04920370)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06208488Phase 1Nov 22, 2023Alexion, Parexel
NCT05556096Phase 3Nov 21, 2022Alexion
NCT05314231Phase 1Jun 29, 2022Alexion
NCT04920370Phase 1Sep 4, 2019Alexion
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AlexionFor profit4422019
ParexelFor profit1012023
2 organizations
Page 1 / 1